Events - Pharvaris N.V.

Upcoming Events

Sep 15, 2026 7:45 PM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Sep 16, 2026 8:00 AM EDT

H.C. Wainwright 28th Annual Global Investment Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Past Events

Feb 9 - Feb 13, 2025

Western Society of Allergy, Asthma & Immunology (WSAAI) 2025 Annual Meeting

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study 748.6 KB

Dec 12 - Dec 15, 2024

APAAACI 2024 International Congress

Supporting Materials

RAPIDe-2 Study: Long-term Efficacy and Safety of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks 1.6 MB

Prophylaxis of Hereditary Angioedema Attacks With Oral Deucrictibant: Efficacy and Quality-of-Life Results from CHAPTER-1 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: The CHAPTER-1 Open-Label Extension Study 1.4 MB

RAPIDe-3 Phase 3 Trial Design: Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 233 KB

Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs Standard of Care in People Living with Hereditary Angioedema 646.2 KB

Dec 9 - Dec 10, 2024

BSI-CIPN Conference 2024

Supporting Materials

Characterizing the patient experience with current treatment of hereditary angioedema attacks in the United Kingdom 686.5 KB

Nov 17 - Nov 20, 2024

ISPOR Europe 2024

Supporting Materials

Challenges in Identifying Information to Build Economic Evaluations in Hereditary Angioedema 225.5 KB

Nov 6 - Nov 9, 2024

79th Annual CSACI Scientific Meeting

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of HAE Attacks: Results of CHAPTER-1 Phase 2 238.1 KB

Long-term safety and efficacy of oral deucrictibant, a bradykinin B2 receptor antagonist, for prophylaxis in HAE: CHAPTER-1 extension study results 229.5 KB

Long-term efficacy and safety of oral bradykinin B2 receptor antagonist deucrictibant in treatment of HAE attacks: RAPIDe-2 extension study results 598.5 KB

Nov 6 - Nov 9, 2024

SEAIC International Symposium

Supporting Materials

Characterizing Patient Treatment of Hereditary Angioedema Airway Attacks 521.2 KB

Investigating the Burden of Disease in People Living With Hereditary Angioedema and their Caregivers in Europe 530.7 KB

Oct 24 - Oct 28, 2024

ACAAI Annual Scientific Meeting 2024

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Hereditary Angioedema Prophylaxis: CHAPTER-1 Open-Label Extension Study 265.2 KB

Long-Term Treatment of Hereditary Angioedema Attacks With Oral Deucrictibant: RAPIDe-2 Extension Study Results 202.9 KB

CHAPTER-1 Phase 2 Trial of Oral Bradykinin B2 Receptor Antagonist Deucrictibant for Hereditary Angioedema Prophylaxis 182.3 KB

Prophylactic Treatment With Oral Deucrictibant Improves Hereditary Angioedema Disease Control and Health-Related Quality of Life 549.8 KB

The Bradykinin Challenge Model In Non-Human Primates Successfully Predicted Efficacious Doses of Deucrictibant in Humans 1.1 MB

Development Of A Novel Kinin Biomarker Assay For Characterization Of Bradykinin-Mediated Disorders 186.1 KB

Development of a HMWK Capillary Immunoblotting Assay for Characterization of Bradykinin-Mediated Disorders 232.9 KB

Oct 23, 2024 from 10:00 AM to 11:30 AM EDT

Virtual Investor Event: Deucrictibant for the Prophylactic and On-Demand Treatment of Hereditary Angioedema (HAE) Attacks and Current HAE Market Dynamics and Unmet Need

Click for Webcast

Supporting Materials

Pharvaris Virtual Investor Day Presentation 1.4 MB

Oct 18 - Oct 20, 2024

73rd Annual Meeting of Japanese Society of Allergology

Supporting Materials

Efficacy and Safety of Oral Deucrictibant Immediate-Release Capsule in Hereditary Angioedema: RAPIDe-3 Phase 3 Clinical Trial Design 637.6 KB

Oct 4 - Oct 5, 2024

2024 Global Angioedema Forum – HAEi Global Leadership Workshop

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study (Oral) 1.4 MB

Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study (Poster) 678 KB

Long-Term Safety and Efficacy of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study (One-Pager) 407.1 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (Oral) 1.5 MB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (Poster) 285.9 KB

Long-Term Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study (One-Pager) 616.9 KB

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 279.6 KB

Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 587.5 KB

Propensity Score-Matched Comparison of Outcomes for Deucrictibant vs. Standard of Care in People Living with Hereditary Angioedema 434.3 KB

Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 332.1 KB

Pagination

First page
Previous page
…
Page 4
Page 5
Current page 6
Page 7
Page 8
…
Next page
Last page